

DEVELOPMENT OF METHOD FOR ANALYSIS AND QUANTIFICATION OF CEFADROXIL IN DIFFERENT PHARMACEUTICAL FORMULATIONS USING HPLC

Viswanath Vittaladevaram* and Hemanth Pragada

^{1,2} Jain Institute of Vocational and Advanced Studies, #127/3, Bull Temple Road, Chamarajpet, Bangalore-560019

*Corresponding Author Email: viswa.vittal@gmail.com

ABSTRACT

A rapid, accurate and sensitive method has been developed for the quantitative determination of Cefadroxil (first generation) in different pharmaceutical formulations. An C-18 ODS, 4.60*250 micro meter analytical column was used with an eluting system consisting of a mixture of phosphate buffer (pH 4.8)-Methanol-Acetonitrile 95-3-2 % (v/v) at a flow rate 1ml/min. Detection was performed by UV-Vis Detector at 230nm, for Cefadroxil per 20microlitre injection. The proposed method is suited both for the determination of Cephalosporins in a wide variety of commercial dosage forms and for the investigation of related compounds and other impurities in Cephalosporins.

KEY WORDS


Cefadroxil, C 18 ODS Column, Chromatogram, Retention time

1. INTRODUCTION:

Cefadroxil is semi synthetic antibiotic classified under Cephalosporin group of pharmaceuticals. Cefadroxil exhibits antibacterial property and it is used for treatment of susceptible bacterial infections such as Strep throat which is caused mainly due to

Streptococcus pyogenes bacteria. Chemically it is designated as 5-thia-1-azabicyclo [4.2.0] oct-2-ene-carboxylic acid, 7- [[amino (4-hydroxyphenyl) acetyl] amino]-3-methyl-8-oxo-, monohydrate, [6R- [6alpha, 7beta(R*)]]- [1-7]. The chemical structure of the Cefadroxil is illustrated below in **Figure 1**.

Figure 1: Chemical structure of Cefadroxil



The molecular formula of Cefadroxil is C₁₆H₁₇N₃O₅S and molecular weight of the compound is 363.38 g/mol. Cefadroxil is available in the form of capsules which are primarily used for the treatment of skin infections caused due to Streptococci and Staphylococci species [1-4]. In addition to this Cefadroxil is used for urinary tract infections

caused by E.coli, Proteus mirabilis and klebsiella species. The half-life time of Cefadroxil is 1.5 hours. The review of literature suggested that quantification of Cefadroxil was reported in biological fluids (human blood serum and urine) [2, 4, 7] and pharmaceutical compounds [2-7]. All these methods used liquid chromatography procedures specifically

by using HPLC (High performance liquid chromatography) and also indicated that best results were observed by application of reverse phase High performance liquid chromatography (RP-HPLC) procedures. Literature review studies indicated that all these methods still require changes with regard to mobile phase composition, flow rate since they are found to be not efficient and economical.

2. Materials and Method:

2.1 Aim and Objective:

To develop a method for the analysis and quantification of Cefadroxil in different pharmaceutical formulations.

2.2 Instrumentation and Software:

Waters HPLC system is used for development of method and validation of Cefadroxil. By using Breeze system software version 3.3 signal output is carefully monitored and processed.

2.3 Requirements:

2.3.1 Materials required:

Column: Waters, C18, 4.6*150mm, 5 micrometer, symmetry, stainless steel

Detector: Waters 2487, Dual absorbance detector

Pump: Waters 1525 Binary HPLC pump

Filters: 0.2micrometer, 47millimeter

2.3.2 Chemicals required:

All chemicals and reagents used for the experiment were of HPLC grade

Acetonitrile (HPLC grade), Methanol, Acetic acid, Monobasic Potassium Phosphate, Orthophosphoric acid, Cefadroxil standard, Milli-Q-Purified water

2.3.3 Other requirements:

Vacuum pump, Sonicator, pH Pen, Weight balance, Tissue paper, reagent bottles, volumetric flasks (10ml), Spatula, Syringe, beakers, micropipette, microtips, distilled water.

2.3.4 Preparation of Mobile Phase:

Solution A: 20mM monobasic PotassiumdihydrogenPhosphate was dissolved in 1000ml of distilled water. To this 1ml of acetic acid is added and thoroughly mixed. The pH of the solution was adjusted to 4.8 using

orthophosphoric acid and solution was mixed and filtered to remove impurities present in the form of gas bubbles.

Solution B: This solution contains only Methanol.

Solution C: This solution contains only Acetonitrile.

Sample solvent: The sample solvent is comprised of mobile phase A: B: C (solutions) present in the ratio of 95:3:2 (%v/v).

2.4 Conditions of Chromatography:

An C-18 ODS (4.60mm x 250mm) analytical column was used with an eluting system consisting of a mixture of phosphate buffer (pH 4.8)-Methanol-Acetonitrile 95-3-2 % (v/v) at a flow rate 1mL/min. The injection volume was 20µL and concentration of working solution is 2 µg/mL. Ambient temperature is maintained and detection was performed by using UV-Visible detector at 230nm for a runtime of 10 min. The retention time of Cefadroxil was 4.17 min.

2.5 Sample Preparation



2.5.1 Standard Stock Preparation: 4mg equivalent of Cefadroxil in 10mL volumetric flask. Then make up the volume with mobile phase and sonicate it.

2.5.2 Preparation of working sample: From the standard stock 50µL is transferred to volumetric flask. Then make up the volume with mobile phase and filter the solution and inject 20µL into the pump.

3. RESULTS AND DISCUSSION:

3.1 Optimization for chromatographic conditions:

To optimize the mobile phase for developing the method for standard Cefadroxil we selected C-18 ODS (4.60 x 250 µm) analytical column in order to reduce the retention time and also to obtain good peaks which are found to be symmetric and exhibit better resolution. The mobile phase is composed of mixture of phosphate buffer (pH 4.8)-Methanol-Acetonitrile 95-3-2 % (v/v) gave good peak tip and both retention time and area is found to be reproducible. The retention time of Cefadroxil was found to be 4.17min. The HPLC chromatogram of standard Cefadroxil was depicted in **Figure 2**.

Figure 2: HPLC Chromatogram of Standard Cefadroxil

Figure 3: Calibration curve of Cefadroxil
 Calibration plot of Cefadroxil


3.2 Method Validation:

As per ICH guidelines the method proposed was validated based on parameters include linearity, accuracy and precision.

3.3 Linearity Plot Analysis:

By using stock solution linearity plot analysis for Cefadroxil were prepared with different (10–100 (µg/mL)) concentration levels. The curves were calibrated by plotting concentrations versus peak area. The values of correlation coefficient, Y-intercept and slope were worked out and value of correlation coefficient is 0.978. The calibration curve is shown in Figure 3.

3.4 Accuracy Estimation:

Recovery analysis procedure was carried out to determine the quality of method and its implementation at different percentage levels

include 50%, 100% and 150% were added. The percentage recovery at three different levels was calculated for Cefadroxil by sample injection. The results were shown in Table 1.

3.5 Precision studies: The standard concentration of Cefadroxil is injected for five times into the column to evaluate the precision by following same chromatographic parameters and percentage of relative standard deviation (%RSD) is calculated. The %RSD will determine the method is reiterated. The % RSD for Cefadroxil assay is 1.01. The results were displayed in Table 2.

3.6 Assay of Cefadroxil Pharmaceutical Formulation: The method proposed is validated and applied for determination of Cefadroxil which is available in tablet dosage form successfully. The results show percentage of Cefadroxil retained and

compared with amounts that are labeled are presented in **Table 3**.

Table 1: Accuracy estimation

Analyte	Percentage level	Nominal value (mg)	Amount present (mg)	percentage of recovery	Mean percentage recovery
Cefadroxil	50%	2.5	2.42	96.8	96.42
	100%	5	4.97	99.4	
	150%	7.5	6.98	93.06	

Table 2: Precision results

Injections	Precision	Precision at intermediate level
1	35584	34378
2	34625	35648
3	35148	34236
4	35012	33634
5	34867	34287
Average	35047	34436
Standard deviation	357.16	737.85
% RSD	1.01	2.14

Table 3: Results of Assay

Compound	Label claim (mg)	Amount present (mg)	Percentage(%) of Assay
Cefadroxil	5.0	4.92	98.4

4. CONCLUSION:

The proposed method found to be most accurate and precise. The method developed and validated in terms of linearity, accuracy and precision for Cefadroxil in different pharmaceutical formulations. The method gave good reproducible retention time and area. The recovery percentage indicates that method developed is free from impurities that are used in the pharmaceutical formulation and thus it clearly suggests that method can be used for Cefadroxil analysis present in either bulk or tablet dosage forms in laboratories.

ACKNOWLEDGEMENT:

We are grateful to Jain Institute of Vocational and Advanced Studies, Jain Group of Institutions, Bangalore, India for providing all facilities to conduct this experiment successfully.

REFERENCES:

- Asha C and Narayana B., A Simple Method for the Spectrophotometric Determination of Cephalosporins in Pharmaceuticals using Variamine Blue, *Ecl. Quim.*, Sao Paulo, 33(2), 41-46, (2008)
- Devaliya R and Jain U., Novel estimation of cefadroxil in tablet dosage forms by RP-HPLC. *Orient J Chem*, 25(4): 1053, (2009).
- El-Shaboury S. R., Saleh G. A., Mohamed F. A. and Rageh A.H., Analysis of Cephalosporin Antibiotics. *J. Pharmaceut. Biomed. Anal.*, 45, 1-19,(2007).
- Espinosa Boscha M, Ruiz Sanchezb A J, Sánchez Rojasc F and Bosch Ojeda C., "Recent developments in the analytical determination of cefadroxil, "Asian Journal of Pharmaceutical Sciences, 3(5), 217-232, (2008).
- Malathi S, Dubey RN, & Venkatnarayanan R., Simultaneous RP-HPLC estimation of Cefpodoxime proxetile and clavulanic acid in tablet. *Indian Journal of Pharmaceutical science*, 71(1), 102-105, (2009).
- Ravi S Shukla, Asha patel, Soni M L, Vishesh modi & Jaliwala Y A., "Quantitative spectrophotometric estimation of cefadroxil using hydrotropic solubilization technique, *Asian Pharmaceutics*, 2(3), 146-147, (2008).
- Shukla RS, Pandey S, Bargale R, Pateland A & Tiwari M., Novel HPLC analysis of cefadroxil in bulk formulation. *Asian J. Pharmaceut*, 2(2), 106, (2008).



***Corresponding Author:**

Viswanath Vittaladevaram* and Hemanth Pragada

Email: viswa.vittal@gmail.com